Beam Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Beam Therapeutics has a total shareholder equity of $981.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.5B and $478.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.19b |
| Equity | US$981.33m |
| Total liabilities | US$478.39m |
| Total assets | US$1.46b |
Recent financial health updates
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Recent updates
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Financial Position Analysis
Short Term Liabilities: BEAM's short term assets ($1.2B) exceed its short term liabilities ($205.6M).
Long Term Liabilities: BEAM's short term assets ($1.2B) exceed its long term liabilities ($272.8M).
Debt to Equity History and Analysis
Debt Level: BEAM is debt free.
Reducing Debt: BEAM has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BEAM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BEAM has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 24.5% each year